{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:00:14Z","timestamp":1791165614997,"version":"4.1.0"},"reference-count":58,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Oxaliplatin (OXL) is a key treatment for colorectal cancer but can potentially induce type II hypersensitivity reactions (II-HSRs), leading to immune-mediated cytopenias. The prevalence and management of OXL-induced II-HSRs remain poorly understood, with evidence being mainly anecdotal and lacking a systematic approach. This study examines the prevalence, clinical presentation, diagnosis, and management of OXL-induced II-HSRs in our population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We prospectively analysed a cohort of OXL-reactive patients at our Drug Hypersensitivity and Desensitisation Centre between January 2019 and April 2024. Patients with clinical and laboratory findings suggestive of II-HSR were included and classified into acute immune thrombocytopenia (AIT), immune haemolytic anaemia (IHA), Evans syndrome (ES), or drug-induced thrombotic microangiopathy (DITMA). Drug-dependent antibodies (DDAbs) were detected via flow cytometry. Carefully selected patients underwent re-exposure to OXL under allergy care and special safety measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Sixteen patients were diagnosed with II-HSRs, with a prevalence of 9.5% among OXL-reactive patients. The mean number of OXL cycles at onset was 20. Atypical hypersensitivity symptoms such as chills, fever, and back pain aided clinical identification. AIT was the most common presentation (56%), followed by ES (38%), and one case of DITMA (6%). DDAbs were detected in 86% of cases, with two patients showing DDAbs to other drugs. Five selected patients were re-exposed to OXL without significant complications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>OXL-induced II-HSRs are rare but pose diagnostic and management challenges. This study shows the importance of early identification, the potential role of DDAbs testing, and the feasibility of re-exposure under controlled conditions in selected patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1605690","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:35Z","timestamp":1756446395000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Oxaliplatin-induced type II hypersensitivity in colorectal cancer: a cohort study on clinical presentation, diagnosis, and management"],"prefix":"10.3389","volume":"16","author":[{"given":"Paula","family":"V\u00e1zquez-Revuelta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Madrigal-Burgaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Carlos","family":"Ruffinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enric","family":"Casanovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Coloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Lleonart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1177\/000313481107700106","article-title":"Oxaliplatin-induced immune thrombocytopenia in a patient with colon cancer","volume":"77","author":"Akdeniz","year":"2011","journal-title":"Am. Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/JTH.12052","article-title":"A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia","volume":"11","author":"Arnold","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"B3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/JTH.12852","article-title":"Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTH","volume":"13","author":"Arnold","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"B4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMRA066469","article-title":"Drug-induced immune thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B5","article-title":"Type II hypersensitivity reaction","author":"Bajwa","year":"2024"},{"key":"B6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/J.CLCC.2013.09.002","article-title":"Fatal oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report","volume":"12","author":"Baretta","year":"2013","journal-title":"Clin. Colorectal Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.clcc.2016.02.001","article-title":"Oxaliplatin immune-induced syndrome occurs with cumulative administration and rechallenge: single institution series and systematic review study","volume":"15","author":"Bencardino","year":"2025","journal-title":"Clin. Colorectal Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/CAD.0B013E3280102F4B","article-title":"Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: a case report","volume":"18","author":"Buti","year":"2007","journal-title":"Anticancer Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/J.1537-2995.2004.03111.X","article-title":"An immediate hemolytic reaction induced by repeated administration of oxaliplatin","volume":"44","author":"Chen","year":"2004","journal-title":"Transfus. Paris."},{"key":"B10","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/CAD.0B013E3280E9496D","article-title":"Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature","volume":"18","author":"Cobo","year":"2007","journal-title":"Anticancer Drugs"},{"key":"B11","first-page":"575","article-title":"Classification of allergic reactions responsible for drug hypersensitivity reactions","volume-title":"Clinical aspects of Immunology","author":"Coombs","year":"1968"},{"key":"B12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMOA073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/AJH.20516","article-title":"Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin","volume":"81","author":"Curtis","year":"2006","journal-title":"Am. J. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/10245332.2017.1419600","article-title":"A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia","volume":"23","author":"Curtis","year":"","journal-title":"Hematology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/BLOOD-2017-10-812461","article-title":"Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies","volume":"131","author":"Curtis","year":"","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6904-6-5","article-title":"Hemolytic uremic syndrome following the infusion of oxaliplatin: case report","volume":"6","author":"Dahabreh","year":"2006","journal-title":"BMC Clin. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(99)03827-1","article-title":"Oxaliplatin-induced haemolytic anaemia","volume":"354","author":"Desrame","year":"1999","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/ANNONC\/MDF018","article-title":"Multicentre phase II study of oxaliplatin as a single-agent in cisplatin\/carboplatin +\/- taxane-pretreated ovarian cancer patients","volume":"13","author":"Dieras","year":"2002","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/ALL.15970","article-title":"Changing patterns in the epidemiology of drug allergy","volume":"79","author":"Do\u00f1a","year":"2024","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4103\/0973-1482.154056","article-title":"Oxaliplatin-induced acute thrombocytopenia","volume":"12","author":"Erdem","year":"2016","journal-title":"J. Cancer Res. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/J.PATHOL.2017.02.005","article-title":"Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update","volume":"49","author":"Favaloro","year":"2017","journal-title":"Pathology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/IJC.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/1078155213520262","article-title":"Oxaliplatin-induced immune-mediated cytopenias: a case report and literature review","volume":"21","author":"Forcello","year":"2015","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.22.02759","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"41","author":"Goldberg","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/S10157-012-0620-8","article-title":"A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin","volume":"16","author":"Ito","year":"2012","journal-title":"Clin. Exp. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1111\/ALL.14644","article-title":"Interleukin-6: a novel biomarker for monoclonal antibody and chemotherapy-associated hypersensitivity confirms a cytokine release syndrome phenotype-endotype association","volume":"76","author":"Jakubovic","year":"2021","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.04.005","article-title":"Drug hypersensitivity in the fast lane what clinicians should know about phenotypes","author":"Jakubovic","year":"2025","journal-title":"endotypes, biomarkers"},{"key":"B29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.3816\/CCC.2009.N.037","article-title":"Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect?","volume":"8","author":"James","year":"2009","journal-title":"Clin. Colorectal Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/ANNONC\/MDS074","article-title":"Oxaliplatin-related thrombocytopenia","volume":"23","author":"Jardim","year":"2012","journal-title":"Ann. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/ALL.15940","article-title":"Differential presentation of hypersensitivity reactions to carboplatin and oxaliplatin: phenotypes, endotypes, and management with desensitization","volume":"79","author":"Jimenez-Rodriguez","year":"2024","journal-title":"Allergy"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1111\/ALL.15889","article-title":"Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper","volume":"78","author":"Jutel","year":"2023","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/164_2021_510","article-title":"Allergy: type I, II, III, and IV","volume":"268","author":"Knol","year":"2022","journal-title":"Handb. Exp. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1200\/JCO.2012.48.3248","article-title":"Acute oxaliplatin-induced thrombotic thrombocytopenic purpura: a case report and results from a cytoflourimetric assay of platelet fibrinogen receptor","volume":"31","author":"Lucchesi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"100640","DOI":"10.1016\/J.WAOJOU.2022.100640","article-title":"Standards for practical intravenous rapid drug desensitization and delabeling: a WAO committee statement","volume":"15","author":"Madrigal-Burgaleta","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/J.CLCC.2014.09.011","article-title":"Oxaliplatin-related acute disseminated intravascular coagulation syndrome in a patient with metastatic colon cancer","volume":"14","author":"Malkhasyan","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/J.1537-2995.2005.04373.X","article-title":"Oxaliplatin-induced immune pancytopenia","volume":"45","author":"Mansouri Taleghani","year":"2005","journal-title":"Transfus. Paris."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0552","article-title":"Pilot experience using drug provocation testing for the study of hypersensitivity to chemotherapy and biological agents","volume":"31","author":"Mart\u00ed-Garrido","year":"2020","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1177\/1078155210381287","article-title":"Oxaliplatin-induced acute thrombocytopenia","volume":"17","author":"Mason","year":"2011","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMra040958","article-title":"Systemic therapy for colorectal cancer","volume":"352","author":"Meyerhardt","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/SJ.BJC.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br. J. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1200\/JCO.2012.42.5082","article-title":"Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review","volume":"30","author":"Niu","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/ALL.15113","article-title":"Hypersensitivity reactions to chemotherapy: an EAACI position paper","volume":"77","author":"Pagani","year":"2022","journal-title":"Allergy"},{"key":"B44","first-page":"4","article-title":"Oxaliplatin: mechanism of action and antineoplastic activity","volume":"25","author":"Raymond","year":"1998","journal-title":"Semin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"AB57","DOI":"10.1016\/j.jaci.2022.12.181","article-title":"Assessing our chemotherapy and biologics drug desensitization center","volume":"151","author":"Revuelta","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/J.CLCC.2019.11.001","article-title":"Oxaliplatin-induced Evans syndrome: a possible dual mechanism","volume":"19","author":"Rousseau","year":"2020","journal-title":"Clin. Colorectal Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/S13256-022-03309-7","article-title":"Oxaliplatin-induced thrombotic microangiopathy: a case report","volume":"16","author":"Saad","year":"2022","journal-title":"J. Med. Case Rep."},{"key":"B48","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1517\/14740338.5.5.687","article-title":"Hypersensitivity reactions associated with oxaliplatin","volume":"5","author":"Saif","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"B49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1533-0028(11)70349-8","article-title":"Oxaliplatin-mediated autoimmune thrombocytopenia","volume":"8","author":"Saif","year":"2009","journal-title":"Clin. Colorectal Cancer"},{"key":"B50","first-page":"3115","article-title":"Fatal thrombocytopenia after oxaliplatin-based chemotherapy","volume":"28","author":"Shao","year":"2008","journal-title":"Anticancer Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.jaip.2020.02.013","article-title":"Endophenotyping oxaliplatin hypersensitivity: personalizing desensitization to the atypical platin","volume":"8","author":"Silver","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/J.CLCC.2020.07.007","article-title":"Oxaliplatin-induced immune thrombocytopenia: a case report and literature review","volume":"20","author":"Stack","year":"2021","journal-title":"Clin. Colorectal Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2169\/INTERNALMEDICINE.52.8933","article-title":"Oxaliplatin-induced acute thrombocytopenia: a case report and review of the literature","volume":"52","author":"Suzuki","year":"2013","journal-title":"Intern Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/JJCO\/HYQ162","article-title":"Sudden-onset pancytopenia with intracranial hemorrhage after oxaliplatin treatment: a case report and literature review","volume":"41","author":"Teng","year":"2011","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/S12032-009-9263-3","article-title":"Acute renal failure related to oxaliplatin-induced intravascular hemolysis","volume":"27","author":"Ulusakarya","year":"2010","journal-title":"Med. Oncol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.021","article-title":"Delabeling patients from chemotherapy and biologics allergy: implementing drug provocation testing","author":"V\u00e1zquez-Revuelta","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.18176\/JIACI.0860","article-title":"A pilot experience using a one-bag intravenous rapid desensitization protocol for chemotherapeutics and biologics in a cohort of patients with access to a delabeling pathway","volume":"33","author":"V\u00e1zquez-Revuelta","year":"2022","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.iac.2021.12.004","article-title":"The who, what, where, when, why, and how of drug desensitization","volume":"42","author":"Yang","year":"2025","journal-title":"Immunol. Allergy Clin. North Am."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605690\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:46:36Z","timestamp":1756446396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1605690\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":58,"alternative-id":["10.3389\/fphar.2025.1605690"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1605690","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1605690"}}